Here we define two cases with a diffuse soft tissue uptake of I-131 in neck and mediastinum on post ablation scan. A diffuse uptake of I-131 in the soft tissue is very rare. In this case report we review the literature and discuss the mechanism of the uptake.

The activity per unit mass of an iodine-131 solution was absolutely standardized by both the 4πβ-γ coincidence method and the 4πγ counting technique. The calibrated solution was used to prepare point sources after a preliminary deposit of AgNO3 to prevent the loss of volatile iodine. Relative and absolute photon emission intensities of 15 sgamma-rays and those of the two K X-rays of xenon were ...

BACKGROUND Iodine-131 ((131)I) is a well-established method for the treatment of hyperthyroidism. Following such therapy, patients may experience symptoms relating to early or delayed side effects that can be prevented or minimized if necessary measures are taken. We have noticed an unusual side effect of (131)I therapy in the form of a skin eruption (iododerma) and aimed at assessing the frequ...

UNLABELLED The purpose of this study was to determine the orogastric transit time of standard 131I capsules and the incidence of transit delay. METHODS We studied 58 consecutive subjects receiving outpatient diagnostic and therapeutic 131I dosages. A standard ion chamber survey meter, placed over the left upper quadrant of the abdomen, monitored orogastric transit. Each subject had ample wate...

A 73-y-old patient who had thyroid carcinoma had a post-treatment, whole-body 131I scan. The scan demonstrated an artifact caused by a bracelet contaminated with radioactive perspiration. This finding resulted in an artifact on the scan and had potential radiation safety implications.

BACKGROUND Radioactive iodine 131 ((131)I) therapy has long been used in the treatment of differentiated thyroid cancers (DTC). While salivary and lacrimal glandular complications secondary to (131)I therapy are well documented, there is little in the literature addressing nasolacrimal duct obstruction (NLDO). We aimed to evaluate the frequency of (131)I therapy-acquired NLDO, its correlation t...

Bone is the second most frequent target of distant metastases in patients with differentiated thyroid cancer, and such forms carry a very poor prognosis. The impact of (131)I therapy in this setting is controversial. We describe the diagnostic circumstances and outcome of patients with bone metastases recently managed in two institutions. Among 921 consecutive thyroid cancer patients who had to...

RATIONALE Iodine-131 (I-131) is a sensitive marker for the detection of differentiated thyroid cancer (DTC). I-131 whole-body scintigraphy (WBS) has been used widely in evaluation of DTC patient. However, I-131 WBS exists many false-positive uptake of I-131 because radioiodine uptake can also be seen in healthy tissue or in a variety of benign and malignant non-thyroidal tumors. PATIENT CONCE...

Thyroxine is bound to a serum protein which appears in the electrophoretogram just ahead of alpha-2 globulin (1-4). Triiodothyronine also associates with this thyroxine binding globulin (T.B.G.) but can be displaced readily with thyroxine -while triiodothyronine will not readily displace thyroxine. Deiss, Albright, and Larson (5) suggested that the firm binding of thyroxine to T.B.G. might acco...